ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0685

Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention

Areeka Memon1, Monique Hinchcliff2 and Amir Masoud3, 1Yale New Haven Health, New Haven, CT, 2Yale School of Medicine, Westport, CT, 3Hartford Healthcare, hartford

Meeting: ACR Convergence 2025

Keywords: Scleroderma, Scleroderma, Localized, Scleroderma, Systemic, Surveys, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Gastrointestinal tract (GIT) symptoms impact up to 90% of individuals with SSc. Hiatal hernia, decreased esophageal contractility, and lower esophageal sphincter tone contribute to dysphagia and gastroesophageal reflux disease (GERD) reducing quality-of-life.Nissen fundoplication is often avoided in SSc due to risk of worsening dysphagia. Transoral incisionless fundoplication (TIF) with the EsophyX System (EndoGastric Solutions Redmond, WA, USA), in conjunction with hiatal hernia repair—termed cTIF—was employed to treat SSc patients with refractory GERD. The EsophyX System offers an alternative treatment option by enabling fasteners to be placed endoscopically at the gastroesophageal junction, resulting in partial recreation of the lower esophageal sphincter at less than or equal to 270 degrees. This approach avoids generating high distal esophageal pressures, which is important in SSc, where esophageal hypomotility increases risk of outflow obstructions and dysphagia. We present a case series highlighting effective use of cTIF for patients with SSc.

Methods: We retrospectively identified patients who fulfilled 2013 ACR/EULAR SSc Classification Criteria and underwent cTIF using the EsophyX System between February 2023 to March 2024. Esophagram, EGD with high-resolution manometry, 24-hour impedance testing, and functional luminal imaging probe plethysmography data were queried. At a mean (SD) post procedure follow-up of 23 (5) months, patients completed the GERD-HRQL survey, a 16-item questionnaire. Patients reported their current (post-procedure) symptoms and retrospectively assessed pre-procedure burden. Small sample sizes precluded formal statistical testing.

Results: Six patients with refractory GERD and/or dysphagia despite medical management who underwent cTIF were identified (Table 1). Esophagrams (n=6) revealed dysmotility in three, and narrowed GE junction in two, patients. Esophageal manometry (n=2) revealed ineffective esophageal motility in one patient and normal in another. pH impedance (n=2) revealed severe GERD per upright acid exposure time in both patients (Table 2). One patient had gastroesophageal intussusception that resolved post-cTIF (Figure 1).At follow-up, one patient had died of respiratory failure, and one patient did not complete, and four completed the GERD-HRQL. The mean (SD) GERD-HRQL pre- vs. post-procedure was 62(4.39) and 19.25(16.29), respectively. Improvement in scores ranged from 30% to 90%, exceeding the minimal clinically important difference.

Conclusion: cTIF appears to be a promising treatment for refractory GERD and dysphagia in SSc. No patient reported worsening dysphagia, and four patients reported overall improvement in symptoms. These outcomes suggest cTIF may safely and effectively fill a critical treatment gap for patients with refractory SSc-GERD.

Supporting image 1pre and post cTIF endoscopy photos revealing improvement of the gastric contents intussuscepting through the esophagus

Supporting image 2baseline characteristics

Supporting image 3Summary of pre-procedure esophageal function testing, including esophagram findings, pH study results (acid exposure time), high-resolution manometry (Chicago Classification), and functional luminal imaging probe (FLIP) assessment, alongside procedural wrap degree following cTIF intervention.


Disclosures: A. Memon: None; M. Hinchcliff: AbbVie/Abbott, Boehringer Ingelheim, Kadmon,, 2, 5; A. Masoud: None.

To cite this abstract in AMA style:

Memon A, Hinchcliff M, Masoud A. Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/targeting-refractory-reflux-in-systemic-sclerosis-early-outcomes-following-a-novel-intervention/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeting-refractory-reflux-in-systemic-sclerosis-early-outcomes-following-a-novel-intervention/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology